Carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in very platinum-sensitive ovarian cancer patients: Results from a subset analysis of the CALYPSO phase III trial

European Journal of Cancer

Volumn 51, Issue 3, 2015, Pages 352-358

  Mahner, Sven ^a   Meier, Werner ^b   Du Bois, Andreas ^c   Brown, Chris ^d   Lorusso, Domenica ^e   Dell'Anna, Tiziana ^f   Cretin, Jacques ^g   Havsteen, Hanne ^h   Bessette, Paul ⁱ   Zeimet, Alain G ^j   Vergote, Ignace ^k   Vasey, Paul ^l   Pujade Lauraine, Eric ^m   Gladieff, Laurence ⁿ   Ferrero, Annamaria ^o  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b Children s Hospital   (Germany)

^c KLINIKEN ESSEN MITTE   (Germany)

^d ANZGOG NHMRC   (Australia)

^e NATIONAL CANCER INSTITUTE   (Italy)

^f SAN GERARDO HOSPITAL   (Italy)

^g Group d'Investigateurs Nationaux Pour l'Etude des Cancers Ovariens (GINECO) Clinique Valdegourue   (France)

^h UNIVERSITY OF COPENHAGEN   (Denmark)

ⁱ UNIVERSITÉ DE SHERBROOKE   (Canada)

^j UNIVERSITY OF INNSBRUCK   (Austria)

^k UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^l Wesley Medical Centre   (Australia)

^m UNIVERSITÉ PARIS DESCARTES   (France)

ⁿ INSTITUT CLAUDIUS REGAUD   (France)

^o MAURIZIANO HOSPITAL   (Italy)

more..

Author keywords

CALYPSO; Carboplatin; Ovarian cancer; Paclitaxel; Pegylated liposomal doxorubicin; Very platinum sensitive

Indexed keywords

CARBOPLATIN; CREATININE; DOXORUBICIN; PACLITAXEL; MACROGOL DERIVATIVE; PLATINUM DERIVATIVE;

ABNORMAL LABORATORY RESULT; ADULT; AGED; ALOPECIA; ARTHRALGIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER RECURRENCE; CANCER SURVIVAL; CHEMOSENSITIVITY; CHEMOTHERAPY INDUCED ANEMIA; CHEMOTHERAPY INDUCED EMESIS; CONSTIPATION; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIARRHEA; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HAND FOOT SYNDROME; HUMAN; INFECTION; LEUKOPENIA; MAJOR CLINICAL STUDY; MOTOR NEUROPATHY; MUCOSA INFLAMMATION; MYALGIA; NAUSEA; NEUTROPENIA; OVARY CANCER; OVERALL SURVIVAL; PAIN; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; SENSORY NEUROPATHY; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT DURATION; VERY ELDERLY; ADJUVANT CHEMOTHERAPY; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; CYSTADENOCARCINOMA, SEROUS; DRUG EFFECTS; DRUG RESISTANCE; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; MIDDLE AGED; MULTICENTER STUDY; OVARIAN NEOPLASMS;

ADULT; AGED; AGED, 80 AND OVER; CARBOPLATIN; CHEMOTHERAPY, ADJUVANT; CYSTADENOCARCINOMA, SEROUS; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; HUMANS; MIDDLE AGED; OVARIAN NEOPLASMS; PACLITAXEL; PLATINUM COMPOUNDS; POLYETHYLENE GLYCOLS; RECURRENCE;

EID: 84922633086     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2014.11.017     Document Type: Article

References (19)

1. International Collaboration for Ovarian Neoplasia Group Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial Lancet 361 2003 2099 2106
2. J. Pfisterer, M. Plante, and I. Vergote Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG J Clin Oncol 24 2006 4699 4707
3. M. Orlando, M.V. Costanzo, and R.D. Chacon Randomized trials of combination chemotherapy (combo) versus monotherapy (mono) in relapsed ovarian carcinoma (ROC): a meta-analysis of published data J Clin Oncol 25 Suppl 2007 280s abstr. 5524
4. Advanced Ovarian Cancer Trialists Group Chemotherapy in advanced ovarian cancer: an overview of randomized clinical trials Br Med J 303 1991 884 893
5. Advanced Ovarian Cancer Trialists' Group Chemotherapy in advanced ovarian cancer: four systematic meta-analyses of individual patient data from 37 randomized trials Br J Cancer 78 1998 1479 1487
6. F.M. Muggia, P.S. Braly, M.F. Brady, G. Sutton, T.H. Niemann, and S.L. Lentz Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a gynecologic oncology group study J Clin Oncol 18 2000 106 115
7. J. Pfisterer, and J.A. Ledermann Management of platinum-sensitive recurrent ovarian cancer Semin Oncol 33 Suppl. 6 2006 S12 S16
8. A. du Bois, H.J. Lück, and W. Meier A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer J Natl Cancer Inst 95 2003 1320 1329
9. A.N. Gordon, J.T. Fleagle, and D. Guthrie Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan J Clin Oncol 19 2001 3312 3322
10. A. Gordon, M. Tonda, and S. Sun Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer Gynecol Oncol 95 2004 1 8
11. J.M. Ferrero, B. Weber, and J.F. Geay Second-line chemotherapy with pegylated liposomal doxorubicin and carboplatin is highly effective in patients with advanced ovarian cancer in late relapse: a GINECO phase II trial Ann Oncol 18 2007 263 268
12. G. Ferrandina, M. Ludovisi, and D. Lorusso Phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in progressive or recurrent ovarian cancer J Clin Oncol 26 2008 890 896
13. B. Weber, A. Lortholary, and F. Mayer Pegylated liposomal doxorubicin and carboplatin in late-relapsing ovarian cancer: a GINECO group phase II trial Anticancer Res 29 2009 4195 4200
14. E. Pujade-Lauraine, U. Wagner, and E. Aavall-Lundqvist Pegylated liposomal doxorubicin and carboplatin compared with paclitaxel and carboplatin for patients with platinum-sensitive ovarian cancer in late relapse J Clin Oncol 28 2010 3323 3329
15. U. Wagner, C. Marth, and R. Largillier Final overall survival results of phase III GCIG CALYPSO trial of pegylated liposomal doxorubicin and carboplatin vs paclitaxel and carboplatin in platinum-sensitive ovarian cancer patients Br J Cancer 107 4 2012 588 591
16. R.F. Ozols, B.N. Bundy, and B.E. Greer Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a gynecologic oncology group study J Clin Oncol 21 2003 3194 3200
17. S. Pignata, S. De Placido, and R. Biamonte Residual neurotoxicity in ovarian cancer patients in clinical remission after first-line chemotherapy with carboplatin and paclitaxel: the Multicenter Italian Trial in Ovarian cancer (MITO-4) retrospective study BMC Cancer 6 2006 5 11
18. P. Power, G. Stuart, and A. Oza Efficacy of pegylated liposomal doxorubicin (PLD) plus carboplatin in ovarian cancer patients who recur within six to twelve months: a phase II study Gynecol Oncol 114 2009 410 414
19. C. Aghajanian, S.V. Blank, and B.A. Goff OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer J Clin Oncol 30 17 2012 2039 2045